Abstract: An extended and expanded USB 3.1 hub includes a housing, a signal transmission module, a first connector and a second connector. The signal transmission module is installed in the housing. The first connector is installed on the housing and electrically connected to the signal transmission module. The second connector is installed on the housing and electrically connected to the signal transmission module. The second connector is used to connect an electronic device, and the first connector and the second connector are both USB 3.1 connectors.

Abstract: A storage module installed with multiple M.2 SSDs includes a frame, at least one circuit assembly, and plural M.2 SSDs. The circuit assembly is fixed to the frame along a direction. The circuit assembly includes plural circuit modules and a power connector. The circuit modules are electrically connected to each other in series. Each of the circuit modules includes a circuit board, a M.2 slot, and a signal connector. The circuit board is fixed to the frame. The M.2 slot is fixed to the circuit board. The signal connector is electrically connected to the circuit board and located outside the frame. The power connector is electrically connected to the circuit board of a corresponding one of the circuit modules. The M.2 SSDs plug into the M.2 slots of the circuit modules respectively.

Abstract: A Peripheral Component Interconnect Express (PCIe) slot expansion system includes a cable adapter, at least one card docking station, and a plurality of standard USB3.0 2-in-1 internal cables. The cable adapter includes a plurality of first PCIe connecting ports and a PCIe male connector, the PCIe male connector is configured to be inserted into a first PCIe slot of a mother board. The card docking station has a width of 5.25 inch. Each card docking station includes: one or two power input port; one or two second PCIe connecting port; and at least one PCI slot or second PCIe slot. Each standard USB3.0 2-in-1 internal cable has a first cable connector and a second cable connector at two opposite ends to be connected with the first connecting port and the second PCIe connecting port respectively.

Abstract: A USB server includes a casing, a motherboard, a PCIe switch host card, a USB to PCIe control card, and a connecting cable. The PCIe control card is inserted on the motherboard and includes a first PCIe bus connecting port. The USB to PCIe control card includes a second PCIe bus connecting port and a plurality of USB receptacle ports. The connecting cable is connected between the first PCIe bus connecting port and the second PCIe bus connecting port, and the USB receptacle ports are located on a front side of the casing.

Abstract: A Peripheral Component Interconnect Express (PCIe) slot expansion system includes a cable adapter, at least one card docking station, and a plurality of standard USB3.0 2-in-1 internal cables. The cable adapter includes a plurality of first PCIe connecting ports and a PCIe male connector, the PCIe male connector is configured to be inserted into a first PCIe slot of a mother board. The card docking station has a width of 5.25 inch. Each card docking station includes: one or two power input port; one or two second PCIe connecting port; and at least one PCI slot or second PCIe slot. Each standard USB3.0 2-in-1 internal cable has a first cable connector and a second cable connector at two opposite ends to be connected with the first connecting port and the second PCIe connecting port respectively.

Abstract: A product obtained by heating at least one substance selected from the following (a), (b) and (c). (a) uronic acid or uronic acid derivative; (b) a saccharide compound containing uronic acid or a saccharide compound containing uronic acid derivative; and (c) a substance containing a saccharide compound containing uronic acid or a substance containing a saccharide compound containing uronic acid derivative; and food, beverage or a pharmaceutical agent which is characterized in containing the above-mentioned heat-treated product.

Abstract: A method for the manufacture of a substance having an apoptosis-inducing ability characterized in including a step of subjecting at least one compound selected from the following (a), (b), (c) and (d) [excluding uronic acid and/or uronic acid derivatives; and compounds which contain uronic acid and/or uronic acid derivatives] to a heating treatment: (a) pentose; (b) pentose derivatives; (c) compounds containing pentose; (d) compounds containing pentose derivatives.

Abstract: The present invention provides a medicament for use as any one of a therapeutic agent or prophylactic agent for a disease requiring enhancement of transforming growth factor-&bgr; production, an agent for amelioration or prevention of wrinkle, an agent for improvement or sustenance of skin elasticity, an agent for amelioration or prevention of epidermal thickening, and a suppressor for decreasing collagen or enhancer for collagen production, and cosmetics used for any one of enhancement of transforming growth factor-&bgr; production, amelioration or prevention of wrinkle, improvement or sustenance of skin elasticity, amelioration or prevention of epidermal thickening, and suppression for decreasing collagen or enhancement for collagen production, and the like, characterized in that each comprises as an effective ingredient one or more members selected from the group consisting of a fucoidan, a degradation product thereof and a salt thereof.

Abstract: A product obtained by heating at least one substance selected from the following (a), (b) and (c).

Abstract: Medicinal compositions for treating or preventing diabetes, rheumatoid, diseases wherein inflammation should be inhibited, diseases wherein &agr;-glycosidase should be inhibited, diseases wherein the synthesis of prostaglandin should be inhibited, diseases wherein endotoxin shock should be inhibited, diseases wherein the production of interleukin should be inhibited, diseases wherein the production of heme oxygenase should be induced, and diseases wherein the production of tumor necrosis factor or carcinogenesis should be inhibited, which contain as the active ingredient at least one compound selected from the group consisting of 3,6-anhydrogalactopyranose represented by formula (I), its aldehyde, its hydrate and 2-O-methylated derivatives and 2-O-sulfated derivatives thereof.

Abstract: A product obtained by heating at least one substance selected from the following (a), (b) and (c). (a) uronic acid or uronic acid derivative; (b) a saccharide compound containing uronic acid or a saccharide compound containing uronic acid derivative; and (c) a substance containing a saccharide compound containing uronic acid or a substance containing a saccharide compound containing uronic acid derivative; and food, beverage or a pharmaceutical agent which is characterized in containing the above-mentioned heat-treated product.

Abstract: An antirheumatic agent which is characterized in containing at least one compound selected from a group consisting of 4,5-dihydroxy-2-cyclopenten-l-one represented by the following formula [I] and an optically active substance and a salt thereof as an effective component.

Abstract: A therapeutic or preventive agent for diabetes mellitus which is characterized in containing at least one compound selected from a group consisting of 4,5-dihydroxy-2-cyclopenten-1-one represented by the following formula [I] and an optically active substance and a salt thereof as an effective component.

Abstract: A compound represented by the following formula [I] or an optically active substance or a salt thereof. (In the formula, a bond shown by a dotted line in the five-membered ring means that said five-membered ring may be any of a cyclopentene ring having a double bond and a cyclopentane ring where said bond is saturated and, in the case of a cyclopentene ring, X is OH, Y is ═O and Z is H while, in the case of a cyclopentane ring, X is ═O, Y is OH and Z is OH. R is a residue after removal of an SH group from the SH-containing compound.

Abstract: There is disclosed a method of manufacturing 4,5-dihydroxy-2-cyclopenten-1-one represented by the following formula [1] which is characterized in that at least one substance selected from the following (a), (b) and (c) is heated.(a): uronic acid or uronic acid derivative(s);(b): a saccharide compound which contains uronic acid and/or uronic acid derivative(s); and(c): a substance containing a saccharide compound which contains uronic acid and/or uronic acid derivative(s).